J&J’s Forecast Disappoints as Actelion Talks Continue

The transcript discusses the impact of currency fluctuations on Remicade's performance, the potential for margin adjustments, and the introduction of biosimilars. It also covers ongoing acquisition talks with Actelion, the influence of political changes under President Trump on the pharmaceutical industry, and Johnson & Johnson's strategic responses to potential policy changes, including tax reform and the Affordable Care Act.

What stance did the CEO take regarding larger deals?

How is the company preparing for potential changes in healthcare legislation?